IndiGo Q1 results today: Focus on impact of Pahalgam and Operation Sindoor
However, a look at the numbers shows that Q1 domestic traffic in India grew by 4.41% compared to last year, while IndiGo had an upper hand growing at 10% compared to the same quarter last year. The growth clearly is present, though lower than expected but definitely not muted.
IndiGo carried 2.7 crore domestic passengers in Q1-FY26, a growth of over 10% compared to 2.45 domestic passengers which the airline carried in Q1-FY25. The airline increased its market share from 61% in Q1-FY25 to 64.4% in Q1-FY26. IndiGo had recorded a profit of ₹ 2279 in Q1-FY25 while in Q4-FY25, a traditionally weaker quarter, the profit had surged to ₹ 3067 crore.
April to June was expected to be a bumper quarter for airlines, with flights at an all-time high. However, the terrorist attack in April saw an immediate decline in tourists to Srinagar, which was scheduled to have the highest ever flights in history. IndiGo pulled out flights from Srinagar, like most other carriers.
The last-minute redeployment of flights as well as tourists changing plans led to an impact rarely seen in May. Tourists anticipated a retaliation by Indian armed forces and it came in the form of Operation Sindoor in May.
Over 20 airports including Srinagar, Chandigarh and Amritsar were closed for a few days impacting airlines and their network. These were also the days of very low passenger numbers and people stayed away due to uncertainty. Yet, May recorded higher passengers than last May as well as April, though marginally. June on the other hand continued with the historic trajectory even after the crash of AI171 at Ahmedabad which had led to a lot of speculation around the passenger numbers going down due to anxiety amongst flyers.
As Pakistan closed its airspace for Indian airlines, Air India was the most impacted. IndiGo shut operations to Almaty and Tashkent, overnight. However, impact on IndiGo was much smaller as compared to Air India because of very limited long haul operations and a scattered network.
The airline operates 11% of its departures on international routes and in terms of capacity by ASK (Available Seat Kilometers) 29% of its capacity is deployed on international routes where it carries 12% of its passengers, a number which has kept growing each quarter but it is not as big to get impacted drastically.
It all then boils down to the main question, will IndiGo declare profits or not? All indicators point to profits but wafer thin. The ATF prices are lower by about 14% over the same period last year which will cushion the other negatives of the quarter under discussion. However, the rupee has depreciated between 2% - 3.5% for the same period compared to last year.
The airline has changed its deployment of Stretch, its business class equivalent product. The airline was to induct 45 planes and cover 12 city pairs within India by November. Instead it has started deploying the planes to Singapore and Dubai.
Time and again the airline has said that it is seeing positive feedback for its Stretch product. However, the change in strategy for higher yields on international flights or a function of not having enough passengers on domestic flights will be known over a period of time. The post results analyst call will possibly have a commentary about the performance of its Dreamliner flights to Manchester and Amsterdam, along with the outlook on grounded planes—compensation for which is being accounted as part of income by the airline.
The airline will have to return the three B777s it has on damp lease from Turkish Airlines at the end of August. These flights are being replaced by the A320 family aircraft which will need a technical stop to reach Istanbul. More Dreamliners will enter IndiGo's fleet by September and will the management spill beans on its deployment? All eyes are on the profits and if the airline manages it in four digits or shrinks to three digit profits or worse, does not record any?
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
&w=3840&q=100)
Business Standard
23 minutes ago
- Business Standard
US tariffs should not be cause for disengaging from trade talks, blocs
The fundamental challenge for the Indian economy is to increase productivity and competitiveness premium Business Standard Editorial Comment Mumbai Listen to This Article The tariff rate of 25 per cent, which United States (US) President Donald Trump has decided will be applied to Indian exports to the US, may not, eventually, be the final rate. It may effectively wind up being higher if he carries out his threat to add a surcharge related to India's increasing purchases of Russian oil. It may be lower if New Delhi's negotiators pull some sort of a broader deal together. It is also worth remembering that there will be multiple exceptions to this headline tariff rate. Some goods that compose a large part of India-US trade —
&w=3840&q=100)
Business Standard
23 minutes ago
- Business Standard
Collaboration for future: Isro and India will benefit from Nasa
Artemis signup allows Isro and the fast-growing Indian aerospace sector to bid for Nasa tenders and the famously frugal Indian engineering sector could find opportunities there and pick up new skills Business Standard Editorial Comment Mumbai Listen to This Article The successful launch of the Nisar (Nasa-Isro Synthetic Aperture Radar) satellite from the Satish Dhawan Space Centre marks the second big mission where the two space agencies have joined hands, coming soon after gaganaut Shubhanshu Shukla travelled to the International Space Station on the Axiom 4 mission. This may be the precursor to more cooperation between the agencies, given that India in 2023 signed up for the Artemis Accords. The Artemis Accords provide a common set of principles for civil exploration and use of outer space. While both agencies benefit from cooperation, the Indian Space Research Organisation (Isro) may benefit
India Today
39 minutes ago
- India Today
How Trump tariffs could impact Indian pharma's $8.7 bn dream run
For long, the high-value US market has driven the growth of the storied Indian generic drugs industry, where companies like Cipla, Sun Pharma and Dr Reddy's Laboratories, among others, have successfully challenged hundreds of off-patent drugs in the US and established a soaring business FY24, India exported $8.7 billion (Rs 76,113 crore) worth of pharma products to the US, which comprises over 11 per cent of India's total merchandise exports to that the same period, India exported $77.5 billion (Rs 6.8 lakh crore) worth of merchandise goods to the US and imported $42.2 billion (Rs 3.7 lakh crore) worth of goods from it, resulting in a trade surplus of $35.3 billion (Rs 3 lakh crore) in India's US is India's largest destination for pharma exports, accounting for over 31 per cent of the country's total pharmaceutical exports. As much as 47 per cent of all generics consumed in the US are imported from India. However, the Donald Trump administration's threat of imposition of a 25 per cent reciprocal tariff from August 1 (up from 0 to 6.7 per cent at present) has thrown the Indian pharma industry in a bind. Shares of Indian pharma companies, led by Sun Pharma, fell close to 6 per cent on the NSE (National Stock Exchange) on August 1 following president Trump's statements on the tariff imposition, and his letters to 17 top US pharma companies asking them to reduce their rates in line with what prevailed in other countries. Some fear Trump may send a similar letter to Sun Pharma, which earns as much as 20 per cent of its total revenues from the US Indian industry was hoping against hope that Trump would not hike tariffs on generic drugs since these are life-saving. However, Trump had indicated earlier this year too that tariffs on pharma products would be 25 per cent from April 2 onwards, without pinpointing any nation. He later gave a 90-day reprieve to countries, and the new deadline for the tariffs was put as August imports roughly $800 million worth of pharmaceutical products from the US, and imposes a tariff of 10 per cent. Experts say that even if higher tariffs are imposed on active pharma ingredients (APIs), which are raw materials going into pharma production, India could still be competitive, if tariffs on other API-supplying countries are higher than that of the US will still be dependent on countries like India since the cost of manufacturing certain drugs in the US would be at least six times compared to that of manufacturing the same product in India, say industry US market, which relies heavily on India for APIs and low-cost generics, would struggle to find alternatives, according to Namit Joshi, chairman of Pharmexcil (Pharmaceuticals Export Promotion Council of India). 'Efforts to shift pharmaceutical manufacturing and API production to other countries or within the US will take at least 3-5 years to establish meaningful capacity,' he was quoted in media reports. advertisement'There is no need for panic. The industry should lie low for now since the US has not yet increased the tariffs. Who else can give the US such competitively-priced goods in large quantities and high quality?' Daara Patel, secretary general of the Indian Drug Manufacturers Association, had said in an interview to INDIA TODAY in April. 'Even if it increases up to 10 per cent, the industry should be able to absorb it or pass it on to the US consumers. They would not mind paying for it since it all works on insurance money,' he what if the US decides to go for a higher tariff? 'In case the US raises tariffs beyond 15 per cent, India will have to look at newer markets in East Africa and the Middle East. These markets are neither high value nor high in volumes, but it will be a better option than dealing with an uncertain US market alone,' Patel had saidSubscribe to India Today Magazine- EndsTune InMust Watch
